Table 2.
Risk‐Adjusted Relative Probabilities of Black vs White Patients Receiving Various Therapies for NSTEMI: ARIC Community Surveillance Study, 2000–2014
| NSTEMI Therapies | 2000–2004 | 2005–2009 | 2010–2014 | Trenda |
|---|---|---|---|---|
| RR (95% CI) | RR (95% CI) | RR (95% CI) | P Value | |
| Medical management | ||||
| Aspirin | 0.93 (0.90–0.99) | 0.96 (0.92–1.02) | 0.96 (0.92–1.02) | 0.7 |
| Nonaspirin antiplatelet | 0.76 (0.69–0.86) | 0.78 (0.71–0.86) | 0.75 (0.68–0.84) | 0.3 |
| β‐Blocker | 0.99 (0.93–1.09) | 0.97 (0.93–1.04) | 0.96 (0.93–1.02) | 0.9 |
| Lipid‐lowering agent | 0.80 (0.75–0.88) | 0.99 (0.91–1.10) | 0.92 (0.86–0.99) | 0.4 |
| Invasive management | ||||
| Angiography | 0.75 (0.70–0.83) | 0.76 (0.69–0.84) | 0.67 (0.61–0.74) | 0.8 |
| Revascularization | 0.60 (0.53–0.680 | 0.55 (0.48–0.64) | 0.52 (0.46–0.60) | 0.7 |
Models adjusted for demographics [age, sex, hospital geographic location (Forsyth County, NC; Jackson, MS; Minneapolis, MN; Washington County, MD) and year of admission] and comorbidities and clinical course (diabetes mellitus, acute heart failure/pulmonary edema, cardiogenic shock, and ventricular fibrillation/cardiac arrest). ARIC indicates Atherosclerosis Risk in Communities; CI, confidence interval; NSTEMI, non–ST‐segment–elevation myocardial infarction; RR, relative risk.
Annual trends derived from aggregate risk‐adjusted model (2000–2014), testing the multiplicative interaction between race and calendar year of admission.